A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Latest Information Update: 28 May 2025
At a glance
- Drugs Abemaciclib (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms CLONEVO
Most Recent Events
- 22 May 2025 According to a Caris Life Sciences media release, data from CLONEVO study will be presented at the upcoming 2025 American Society of Clinical Oncology Annual Meeting, from May 30- June 3, in Chicago, IL.
- 30 Apr 2025 Results assessing whole-exome and RNA sequencing of pre and post abema tissues and serial evaluation of ctDNA presented at the 116th Annual Meeting of the American Association for Cancer Research
- 24 Dec 2024 Status changed from recruiting to active, no longer recruiting.